Genmab — Maj 2025

[E_L]

wouldn't it be fun if JNJ would reconsider the hexabody-CD38 option on the back on this CMS draft guidance lol

[E_L]

finally found a Genmab A/S Q1 2025 Earnings Call Transcript -that is not behind a paywall - https://www.marketbeat.com/earnings/reports/2025-5-8-genmab-as-stock/

[E_L]

you have to use your imagination a bit to get trough the spelling mistakes...

[blackadder]

https://web.quartr.com/link/companies/5475/events/315198/transcript?targetTime=0.0

[blackadder]

Jeg bruger denne som en app til min iPhone, der er live streaming og transskription lavet af live streaming, sikkert lavet med et eller andet whisperprogram.

[blackadder]

Det er som at gå at høre podcast for investorer.

[blackadder]

Undskyld jeg spammer chatten. Linket er et direkte link fra mobilappen til Genmab Q1 2025 live event med transskription. Appen er helt gratis at bruge og guf for investornørder

[lahn1]

Fin app !

[ProinvestorNEWS]

C25-regnskaber, 1. kvartal 2025: Karakterbogen https://proinvestor.com/boards/126363

[E_L]

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress https://ir.genmab.com/news-releases/news-release-details/genmab-present-new-and-updated-results-its-robust-epcoritamab

[Helge_LarsenPI-redaktør]

Investeringspodcasten 274: Status på de danske aktier https://proinvestor.com/boards/126364

[Helge_LarsenPI-redaktør]

Genmab: 14.33

[E_L]

EHA 25 embargoed until Thursday, June 12

[E_L]

actually, we can see them now already

[E_L]

maybe i should post the link for the more
lazy people https://library.ehaweb.org/eha/#!*search=epcoritamab*browseby=8*listing=0*sortby=1

[E_L]

EHA25 - EPCORE NHL-5 - Fixed-duration epcor + pola-R-CHP with follow-up of 16.1 mos in pts with newly diagnosed : ORR was 100% with 97% achieving a CR

[E_L]

EHA25 - EPCORE NHL-2 -Epcor + R-ICE demonstrated high CR rates in pts with R/R DLBCL eligible for ASCT, most of whom were high risk, having progressed <12 mo of 1L tx. ORR was 87%; 20 pts (65%) had a CR and 7 (23%) a partial response (PR

[Solsen]

Til sammenligning til EPCORE NHL-2: Background:
First-line (1L) standard of care (SOC) for diffuse large B-cell lymphoma (DLBCL) is rituximab plus C, H, vincristine, and P (R-CHOP), and it continues to evolve with pola-R-CHP showing higher complete response rates (CRR) of 78% and longer progression-free survival (PFS) than R-CHOP (Tilly 2022)

[Solsen]

Certainly looks good

[lahn1]

Kun nået til de 3 første men EPCO i kombi ser ud til at være bedste valg